Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal executive offices in Australia, filed this Form 8-K on March 7, 2022. The filing reports the entry into a material definitive agreement involving a private placement of debt securities.
Key Financial Metrics and Transaction Details
- Debt Instrument: 8% Convertible Promissory Note.
- Principal Amount: $68,750.
- Net Proceeds: $65,000 (after fees and expenses of $3,750).
- Use of Proceeds: General working capital purposes.
- Interest Rate: 8% per annum, payable in cash or shares of common stock upon maturity or acceleration.
- Maturity Date: March 7, 2023.
- Conversion Terms: Convertible at the investor's option starting September 5, 2023, at a variable conversion price equal to 65% of the market price (35% discount).
- Liquidity Impact: The transaction is expected to close on or about March 12, 2022, providing immediate working capital.
Material Changes and Terms
The filing details the creation of a new direct financial obligation. Key terms include:
- Prepayment Penalties: The Note may be prepaid within 180 days of issuance, subject to escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment.
- Default Provisions: Upon certain events of default, the outstanding principal and accrued interest become immediately due at 150% of the amount (the "Default Amount").
- Conversion Cap: The investor is restricted from converting if it would result in beneficial ownership exceeding 4.99% of outstanding common stock.
- Covenants: The Company covenants not to dispose of substantially all assets to become a "shell company" without consent and must maintain listing on an OTC market or equivalent exchange.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary regarding future performance. However, it outlines significant risks and contingencies:
- Dilution Risk: Conversion of the Note at a 35% discount to the market price will result in significant dilution to existing shareholders.
- Default Risk: Failure to deliver shares upon conversion within three business days incurs a penalty of $1,000 per day. Events of default include insolvency, failure to maintain stock listing, or failure to comply with SEC reporting requirements.
- Financial Restatement Risk: Restatement of financial statements filed after 180 days from issuance that materially affects investor rights constitutes an event of default.
Investor Verification Checklist
- Verify the closing of the transaction and receipt of the $65,000 net proceeds.
- Monitor the Company's ability to maintain its listing on an OTC market or equivalent exchange to avoid default.
- Assess the potential dilution impact if the Note is converted at the 35% discount rate.
- Review the Company's cash burn rate to determine if the $65,000 proceeds are sufficient for working capital needs until the March 2023 maturity.
- Confirm the Company's compliance with SEC reporting requirements to prevent triggering default clauses.